Personalized Brain Cancer Vaccine May Help Against Aggressive Glioblastoma
discovermagazine - Discover how a personalized DNA vaccine trained patients’ immune systems to target their own tumors, with one participant remaining cancer-free nearly five years later.
AI Summary: A customized vaccine targeting each patient's tumor has demonstrated encouraging immune responses and signs of clinical benefit against aggressive glioblastoma. Researchers report enhanced T‑cell activity and preliminary survival signals, suggesting personalized neoantigen vaccines may help control this stubborn brain cancer and warrant larger, controlled trials to confirm impact.
- New models and datasets speeding brain tumor research (3)
- Next-gen glioblastoma immunotherapies: CAR T, drugs, stem cells (3)
- Personalized glioblastoma vaccine: early immune and survival signals (3)
- All Other Stories
New models and datasets speeding brain tumor research
Next-gen glioblastoma immunotherapies: CAR T, drugs, stem cells
Personalized glioblastoma vaccine: early immune and survival signals
All Other Stories
A Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved Therapy
Frank Vinluan / medcitynews - Partner Therapeutics’ Bizengri is now FDA approved for treating advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. Partner acquired U.S. rights to this bispecific antibody from Merus in 2024. The post A Cancer Driven by Ultra-Rare Mutation …
AI Summary: The FDA approved zenocutuzumab‑zbco for NRG1‑fusion–positive cholangiocarcinoma, delivering the first cleared therapy for cancers driven by this ultra‑rare genomic alteration. Trial data showed meaningful responses in heavily pretreated patients, prompting regulators to greenlight a precision option that offers targeted benefit where none existed — a small‑population win for genomic oncology.
Study reveals how parenting styles shape babies' willingness to help others
medicalxpress - New research from Durham University shows that the way parents instruct and encourage infants to help plays a key role in how helping behavior develops, and that these approaches vary across cultures.
AI Summary: The RESET‑C trial tested one preoperative dose of pembrolizumab in localized mismatch repair‑deficient colon cancer and recorded unexpectedly high tumor responses, with several patients remaining cancer‑free for nearly three years. The dramatic neoadjuvant activity suggests immune priming could reshape perioperative strategies and raises questions about surgery timing and organ preservation.
National study examines genetic testing to inform follow-up care for cancer survivors
medicalxpress - Hundreds of thousands of people diagnosed with cancer are still alive today but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis. These patients are just as likely as those…
AI Summary: A national study has been launched to assess whether genetic testing can refine follow-up care for cancer survivors, tailoring surveillance to individual risk and potentially reducing unnecessary tests. The large-scale effort seeks to integrate genomic data into survivorship plans to better predict late effects and allocate resources to those most likely to benefit.
- Building survivorship standards, care and advocacy (4)
- Conferences, research and personalized cancer survivorship insights (4)
- National genetic-testing study and genomic implications for survivors (4)
- All Other Stories
Building survivorship standards, care and advocacy
Conferences, research and personalized cancer survivorship insights
National genetic-testing study and genomic implications for survivors
All Other Stories
First-Ever Smell Map Is a Breakthrough in Sensory Research, a Step to Help Us Tackle Loss of Smell
discovermagazine - Discover how smell receptors in our noses aren’t randomly arranged but are highly organized, offering new paths toward treating sensory impairment.
AI Summary: Scientists have produced the first high‑resolution olfactory map, charting how scent receptors and neural circuits are organized in the nose. The atlas exposes unexpected patterns in odor encoding, helps explain smell loss, and points to new diagnostic and therapeutic pathways — including potential early markers of Alzheimer’s‑related olfactory damage.
- Hidden nose atlas rewrites smell organization, flags Alzheimer links (4)
- New brain markers and tests for early Alzheimer detection (4)
- All Other Stories
Hidden nose atlas rewrites smell organization, flags Alzheimer links
New brain markers and tests for early Alzheimer detection
All Other Stories
Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of HNRNPH2-related neurodevelopmental disorder
Ane Korff, Xiaojing Yang, Ozan Ozdemir, Ananya Samanta, Yong-Dong Wang, Tushar Patni, Alfonso J. Lav / science - Science Translational Medicine, Volume 18, Issue 846, April 2026.
AI Summary: Researchers report that antisense oligonucleotide therapy reversed neurological deficits in mouse models of HNRNPH2‑related neurodevelopmental disorder. The preclinical results provide a targeted mechanism to correct pathogenic RNA processing, moving a once‑untreatable condition toward a plausible therapeutic path — pending the usual caution about translating mice to humans.
A machine learning model that uses DNA methylation patterns may help identify the origin of cancers of unknown primary
medicalxpress - A machine learning model analyzing CpG-based DNA methylation accurately predicted the origin of many different cancer types in patients with cancers of unknown primary (CUP), according to research presented at the American Association for Cancer Research …
AI Summary: A machine‑learning model trained on DNA methylation signatures can assign tissue‑of‑origin for cancers of unknown primary with promising accuracy. The approach could speed diagnosis, guide therapy choices and reduce reliance on invasive tests—handy when a tumor refuses to tell doctors where it came from.
- ctDNA and AI for treatment monitoring and early detection (3)
- Liquid biopsies and extracellular vesicles for early cancer detection (4)
- Methylation-based ML to identify cancers' tissue of origin (3)
- All Other Stories
ctDNA and AI for treatment monitoring and early detection
Liquid biopsies and extracellular vesicles for early cancer detection
Methylation-based ML to identify cancers' tissue of origin
All Other Stories
Gene therapy improves hearing in 90% of patients with inherited deafness in largest trial of its kind
livescience - A new gene therapy tested in China has improved the hearing of 38 people who were born deaf due to mutations in a gene called OTOF.
AI Summary: A gene therapy for inherited deafness delivered dramatic results, restoring hearing in roughly 90% of treated patients in the largest trial of its kind. Investigators report durable improvements over follow-up, signaling a potential one-time intervention for certain genetic deafness types and challenging the notion that auditory loss is always irreversible. Hope, meet hard data.
- FDA approves first-ever gene therapy for inherited hearing loss (6)
- Primate study finds human-like genetic cause of blindness (1)
- Trial shows durable hearing restored in most patients (3)